Zak Mir talks to Dr Jim Millen, Non-Executive Chairman, Physiomics PLC

Zak Mir talks to Dr Jim Millen, Non-Executive Chairman, Physiomics PLC

From Share Talk LTD by Share Talk LTD

April 29, 2026 · 7 min

About this episode

Zak Mir interviews Dr Jim Millen about Physiomics and its role in drug development.

Zak Mir talks to Dr Jim Millen, Non-Executive Chairman, Physiomics, regarding recent progress at the mathematical modelling, data science and biostatistics company, and issues regarding the forthcoming requisitioned meeting. What Physiomics actually does Physiomics is a specialised life sciences consultancy that works with companies developing new drugs. At its core, the business helps drug developers make better decisions about how they design and run studies. The company operates across two main areas. Mathematical modelling to support the design of preclinical and clinical trials, with a particular focus on oncology, though not limited to cancer treatment. Biostatistics , covering the statistical design of trials, reporting, planning, and regulatory interactions around trial outcomes. That combination matters. Drug development is expensive, time-consuming and high risk. The more rigorously a company can model likely outcomes and build trials correctly from a statistical standpoint, the better its chances of generating meaningful data and navigating the regulatory process successfully. In simple terms, Physiomics is there to help clients ask the right questions before they…

People in this episode

Host: Zak Mir

Guest: Dr Jim Millen

Topics covered

  • drug development
  • biostatistics
  • mathematical modelling
  • oncology
  • life sciences consultancy

Keywords

  • Physiomics
  • drug trials
  • biostatistics
  • mathematical modelling
  • oncology
  • life sciences

Mentioned in this episode

Organizations: Physiomics PLC, Physiomics

More episodes of Share Talk LTD

Explore listener stats, chart rankings, contacts and more on the Share Talk LTD podcast page.